Peptic Ulcers Treatment Market – By Drug Type, By Ulcer Type, By Medication Type, By Route of Administration, By Distribution Channel - Forecast, 2025 - 2034

Peptic Ulcers Treatment Market Size

The global peptic ulcers treatment market size was valued at USD 5.1 billion in 2024. The market is expected to grow from USD 5.4 billion in 2025 to USD 8.6 billion in 2034 at a CAGR of 5.3%. The substantial growth in the market for peptic ulcer treatments is driven by the increasing adult demographic associated with gastrointestinal disorders coupled with the growing advancement in novel drug development. The rising prevalence rate of Helicobacter pylori (H. pylori) infections that remains a primary cause of peptic ulcers is a major contributor towards growing peptic ulcer treatment demand.
 

As reported by the World Gastroenterology Organization (WGO), H. pylori remain a major health concern infecting more than half of the global population, with higher infection rates observed in developing regions. These rising cases are expected to spur the need for effective treatment addressing global concern.
 

The growing overuse of non-steroidal anti-inflammatory drugs (NSAIDs) can cause the irritation to the stomach lining leading to mucosal damage, further increasing the risk of ulcers. For instance, as reported in NSAID Gastropathy research study, approximately 15% - 30% of patients on long-term NSAIDs develop the risk of peptic ulcers. Thus, the growing concern emphasized the need for effective and fast-acting treatment solutions in the market.
 

The growing advancement in diagnostic technologies coupled with novel drug therapies such as availability of combination therapies, including proton pump inhibitors (PPIs) in combination with antibiotics, is clinically proven to improve the treatment outcomes and reduce recurrence rates. These clinical and socio-economic factors are anticipated to sustain the demand for peptic ulcer treatments across both developed and emerging healthcare markets. Furthermore, the poor dietary patterns, sedentary lifestyle, and rising stress levels are some of the few other factors mounting the risk of upset stomach and related gastrointestinal disorders that is growing the necessity for novel treatment solutions, thereby boosting market growth.
 

Peptic ulcer treatment involves medical strategies designed to heal stomach or duodenal ulcers, relieve symptoms, and reduce the risk of recurrence. The standard approach combines acid-suppressing medications including PPIs such as omeprazole, H2-receptor blockers with antibiotics to address H. pylori, the primary bacterial cause. Over the counter (OTC) antacids can offer rapid relief from symptoms, while cytoprotective drugs, including sucralfate and misoprostol protects the mucosal lining.
 

Peptic Ulcers Treatment Market Trends

• Expanding research and development (R&D) efforts are playing a crucial role in advancing the market. Pharmaceutical companies, academic institutions, and government organizations are actively investing, driving innovation in drug formulations, delivery systems, and therapeutic approaches.
   
• These efforts are leading to the development of effective and targeted treatments, such as combination therapies and other novel therapeutic solutions addressing concerns of peptic ulcer related causes such as H. pylori infections and NSAID-induced ulcers.
   
• For instance, in April 2023, Akums introduced a novel combination therapy, consisting of amoxicillin, clarithromycin, and esomeprazole, designed to effectively treat H. pylori infections and accelerate ulcer healing.
   
• The therapy’s simplified dosing schedule enhances patient adherence, leading to improved treatment outcomes. This advancement in combination therapies is expected to significantly improve peptic ulcer management and address the growing need for more efficient and patient-friendly treatment options.
   
• Also, the clinical trials are being accelerated through collaborative efforts and digital platforms, improving the speed and efficiency of bringing new therapies to the market.
   
• For example, the introduction of potassium-competitive acid blockers (P-CABs), a new category of acid-suppressing medications that provide faster relief and longer-lasting acid control compared to PPIs.
   
• Researchers are investigating innovative therapeutic options designed to strengthen mucosal protection or leverage improved acid suppression techniques. These efforts aim to enhance treatment effectiveness, minimize relapse rates, and offer solutions for patients who do not respond to PPIs.
   
• These breakthroughs represented a shift toward more targeted and efficient therapies, addressing critical gaps in care and improving long-term outcomes for patients. Thus, the aforementioned factors collectively are set to drive long-term growth and strengthen the potential of the market.
   

Peptic Ulcers Treatment Market Analysis

In 2021, the global market was valued at USD 4.5 billion. The following year, it saw a slight increase to USD 4.7 billion and in 2023, the market further climbed to USD 4.9 billion.
 

Based on drug type, the global market is segmented into proton pump inhibitors (PPIs), H2-receptor antagonists, antacids, antibiotics, cytoprotective agents, and other drug types. The PPIs segment dominated the market and was valued at USD 2.3 billion in 2024 and is poised to reach USD 3.7 billion by 2034 at a CAGR of 5.1%.
 

• PPIs are the preferred choice for peptic ulcer treatment due to their proven ability to reduce gastric acid secretion, promote ulcer healing, and alleviate symptoms effectively.
   
• The omeprazole, pantoprazole, and esomeprazole are widely prescribed globally due to their favorable safety profiles and reliable therapeutic outcomes. The growing prevalence of H. pylori infections and the increasing cases of NSAID-induced ulcers continue to drive demand for PPIs.
   
• Various clinical studies also indicated that PPIs used appropriately for 4 - 8 weeks resulted in ulcer healing rates exceeding 90%. Their critical role in triple therapy regimens for H. pylori eradication further strengthens their market leadership.
   
• Further, the availability of branded and generic formulations ensures accessibility across various healthcare settings. As a result, PPIs remain the first-line therapy in most treatment guidelines, maintaining its prominence in the peptic ulcer treatment landscape.

Based on ulcer type, the global peptic ulcers treatment market is categorized into gastric ulcers, duodenal ulcers and esophageal ulcers. The duodenal ulcers segment accounted for the highest market share of 50.8% in 2024 and is poised to grow at a substantial rate during the analysis period.
 

• Duodenal ulcers leadership is driven by their higher prevalence compared to other ulcer types. These ulcers mainly develop in the upper part of the small intestine and are commonly associated with H. pylori infections and prolonged NSAID use.
   
• They affect individuals across a wide age range and often present with noticeable symptoms, such as burning abdominal pain, which facilitates faster diagnosis and treatment.
   
• The effectiveness of PPIs and combination antibiotic therapies in managing these ulcers contributes to high treatment success rates. Their tendency of recurrence is expected to augment the need for long-term therapeutic solutions further propelling the ulcer drugs demand.
   

Based on the medication type, the global peptic ulcers treatment market is categorized by branded and generics. In 2024, the branded segment accounted for the largest share and is poised to grow at a significant growth with a CAGR of 5.1%.
 

• The branded drugs continue to lead the market, particularly in developed countries where patients and healthcare providers prioritize proven efficacy and quality. Medications such as Nexium (esomeprazole), Prevacid (lansoprazole), and Dexilant (dexlansoprazole) are commonly prescribed due to their well-established clinical profiles.
   
• In addition, pharmaceutical companies play a key role in maintaining this dominance by investing heavily in marketing efforts and building strong relationships with healthcare professionals.
   
• Although generic alternatives are becoming more popular, the perception of greater safety and better treatment outcomes maintains branded medications as the preferred choice.
   

Based on the route of administration, the global peptic ulcers treatment market is categorized into oral and parenteral. In 2024, the oral segment dominated the market accounting for the highest revenue of USD 4.2 billion and is anticipated to witness dominance throughout the forecast period at a CAGR of 5%.
 

• The oral route popularity is primarily driven owing to its ease of use, non-invasive nature, and strong patient adherence due to ease of availability and cost-effectiveness.
   
• The drugs such as PPIs, antibiotics, H2-receptor antagonists, and cytoprotective agents, commonly prescribed oral drugs available in tablets and capsule forms.
   
• Furthermore, the ease of accessibility of oral drugs, through OTC or prescriptions supports its leadership in the market.
   

Based on the distribution channel, the global peptic ulcers treatment market is categorized by hospital pharmacies, retail pharmacies, and online pharmacies. In 2024, the retail pharmacies segment accounted for the largest share of 44%.
 

• Retail pharmacies play a critical role by providing patients with convenient access to both OTC and prescription medications.
   
• These pharmacies are often the first preference for individuals seeking rapid relief from ulcer symptoms, with commonly used treatments including PPIs, H2-receptor antagonists, and antacids.
   
• In addition, retail pharmacies frequently act as the initial point of care for self-medication and managing mild to moderate cases particularly in developing countries.
   
• Moreover, the ease of access and the opportunity to consult with pharmacists have solidified retail pharmacies as a trusted and preferred choice for many consumers.

In 2024, North America peptic ulcers treatment market accounted for the largest revenue of USD 2.1 billion and is projected to generate revenue of USD 3.6 billion by 2034 at a CAGR of 5.5% during the analysis period.
 

• North America prominence was driven by the significant prevalence of H. pylori infections and the NSAIDs overuse causing ulcer development.
   
• The region’s prominence is further fueled by its developed healthcare infrastructure, expanded access to advanced therapies and awareness of gastrointestinal health and healthy lifestyle.
   
• The presence of leading pharmaceutical companies further strengthens the market. Therefore, the aforementioned factors collectively strengthen the position of North America as a key player in the global peptic ulcer treatment market.
   

In 2024, U.S. peptic ulcers treatment market accounted for USD 1.9 billion revenue from USD 1.8 billion in 2023 and is anticipated to grow at a CAGR of 5.4% between the 2025 to 2034 period.
 

• The U.S. leadership was asserted due its well-established healthcare infrastructure, healthcare spending, and high incidence rate of gastrointestinal disorders among the U.S. population.
   
• Also, the ease of availability of NSAIDs has driven its widespread use, increasing stress levels, and sedentary lifestyle, unhealthy dietary patterns have contributed to the growing prevalence of peptic ulcers in the country.
   
• Easy access to healthcare services, and greater awareness of early diagnosis and treatment further enhance the demand, firmly establishing the U.S. as a prominent country in the regional market.
   

Germany is poised to achieve significant growth in the Europe peptic ulcers treatment market.
 

• Germany is poised for growth in the coming years driven by combination of high prevalence of gastrointestinal disorder, an aging population, advanced healthcare system, and precise diagnostic capabilities.
   
• The H. pylori infections rate in the country, along with aging demographic underscores the necessity for appropriate treatment. For instance, the burden of AGI is high in adults in Germany, accounting for nearly 9/10 individuals experience an episode each year.
   
• Growing government initiatives, along with the increasing expenditure, also support further country level development.
   

Asia Pacific is poised to grow at a significant growth rate in the global peptic ulcers treatment market over the next few years.
 

• The Asia Pacific region exhibits substantial growth driven by growing healthcare spending, high geriatric demographic with gastrointestinal disorders, and the awareness of early treatment.
   
• The Asian countries such as China and India are witnessing a surge in the gastrointestinal disorder among the adult population due to urbanization and changes in dietary patterns.
   
• Also, growing health awareness, higher income levels, and better healthcare accessibility have enabled early detection and treatment of these conditions.
   
• Further, the region's substantial investments in pharmaceutical research and healthcare facilities support the development of ulcer treatments, including PPIs, antibiotics, and other drugs. These factors contribute to the expansion of the ulcer treatment market in Asia Pacific.
   

China is anticipated to grow significantly within the Asia Pacific peptic ulcers treatment market.
 

• China is set for rapid growth attributed to the expanding ageing demographic, widespread prevalence of H. pylori infection, necessitating demand for early treatment.
   
• According to a study published in an Infectious Agents and Cancer journal, nearly 40-45 % of adults are suffering from H. Pylori infection in China. The statistics emphasize the need for effective treatment strategies focusing on ulcer treatment.
   
• The government initiatives such as “Healthy China 2030” are likely to spur innovation and investments in health awareness programs and diagnostic facilities.
   
• Moreover, the country's robust pharmaceutical industry ensures a steady supply of both branded and generic medications, particularly PPIs, antacids and antibiotics.
   
• As China's population ages and gastrointestinal diseases become more prevalent, the demand for ulcer treatments continues to rise, strengthening the country's position in the regional peptic ulcer treatment market.
   

Brazil is projected to witness significant growth in Latin America peptic ulcers treatment market in coming years.
 

• Brazil growth was driven with growing healthcare awareness programs and medical care accessibility.  The country faces a significant health challenge with the increasing cases of H. pylori infection affecting a larger adult population base, making it a primary concern for peptic ulcer development.
   
• The frequent NSAID consumption, poor dietary habits, and high stress levels, further contribute to ulcer cases.
   
• Also, growing regulatory support and initiative stimulates market demand. For example, the Brazilian public healthcare system (SUS) has strengthened its diagnostic and treatment services, complemented by private sector investments in modern therapies such as PPIs and antibiotic combinations.
   
• With support from the government and established pharmaceutical companies, both local and international, more patients can now access necessary treatments. These factors highlight Brazil's vital role in shaping the regional market's future.
   

Saudi Arabia is anticipated to grow in the Middle East and Africa peptic ulcers treatment market.
 

• Saudi Arabia is set to show prominent growth owing to the increasing cases of gastrointestinal disorders coupled with substantial investments in medical infrastructure and increasing public awareness about gastrointestinal health.
   
• In the surveyed population of Jeddah, Saudi Arabia, a notable proportion of respondents reported being diagnosed with peptic ulcer disease (PUD), comprising 463 individuals, which accounts for approximately 82.53 % of the total respondents (total respondents were 561).
   
• Also, the growing government support and initiative such as to Vision 2030 reforms aimed at modernizing healthcare systems has improved medical facilities and treatment accessibility across the country.
   
• The pharmaceutical landscape in Saudi Arabia continues to expand, with both local and international companies offering various treatment options.
   
• These developments, combined with the government's focus on healthcare improvement has ensured Saudi Arabia as an important market for peptic ulcer treatments in the region.
   

Peptic Ulcers Treatment Market Share

The top 5 players in the global market accounted for ~40% of the share. The peptic ulcer treatment market is highly competitive, with several global pharmaceutical companies offering a variety of therapies, such as PPIs, H2-receptor antagonists, antibiotics, and other drugs. Leading companies like Pfizer, AstraZeneca, Takeda, GlaxoSmithKline, and Dr. Reddy’s Laboratories hold significant market shares, driven by their well-established product portfolios and global presence. The prominent products in this industry such as AstraZeneca’s Nexium and Takeda’s Dexilant, which are among the top-selling PPIs, highlights the continuous development for novel treatment further shaping the market trajectory.
 

Pharmaceutical companies are increasingly prioritizing R&D to develop combination therapies that target H. pylori eradication and acid suppression. The market is also witnessing trends such as strategic partnerships, geographic expansion, and the introduction of innovative therapies with fewer side effects.
 

Peptic Ulcers Treatment Market Companies

Few prominent players operating in the peptic ulcers treatment industry include:

• AstraZeneca
• Aurobindo Pharma
• Azurity Pharmaceuticals
• Cadila Healthcare
• Dr. Reddy’s Laboratories
• Eisai
• GlaxoSmithKline
• Granules India
• Pfizer
• Phathom Pharmaceuticals
• Ranbaxy Laboratories
• Strides Pharma
• Sun Pharma
• Takeda
   
• AstraZeneca’s offer flagship product Nexium and is engaged in advanced R&D in PPIs. The company offers a comprehensive gastrointestinal portfolio, and ongoing innovation in acid suppression therapies, the company continues to be a leader in the peptic ulcer market.
   
• Pfizer’s broad therapeutic portfolio and extensive global manufacturing capabilities allow it to deliver high-quality and accessible treatments for gastrointestinal conditions. Its deep expertise, strong regulatory presence, and focus on developing innovative combination therapies reinforce its position as a leader in addressing NSAID-related ulcer risks and H. pylori eradication.
   
• Strides Pharma is known for its cost-effective generic formulations and a robust portfolio of U.S. FDA-approved products. The recent approval of its generic Sucralfate Oral Suspension further strengthens its position in the ulcer treatment segment, reflecting its dedication to affordability, regulatory compliance, and expanding access to gastrointestinal therapies globally.
   

Peptic Ulcers Treatment Industry News:

• In February 2025, Zydus Lifesciences received U.S. FDA approval to manufacture Ibuprofen and Famotidine tablets. These tablets are designed to treat rheumatoid arthritis and osteoarthritis while reducing the risk of upper gastrointestinal ulcers. This approval enhanced Zydus’s gastrointestinal portfolio, reflecting the growing demand for ulcer-protective therapies and contributing positively to the peptic ulcer treatment market.
   
• In July 2024, Dr. Reddy’s Laboratories entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical to bring Vonoprazan tablets to the Indian market. Vonoprazan, an advanced oral acid blocker, is used to treat reflux esophagitis and other acid-peptic disorders. Dr. Reddy’s will market the product under the brand name VONO, available in 10mg and 20mg strengths. This development expands Dr. Reddy’s acid-peptic treatment portfolio and meets the growing demand for innovative therapies in India’s market.
   
• In May 2024, Strides Pharma, Singapore, received U.S. FDA approval for its generic Sucralfate Oral Suspension, 1gm/10mL. The product is bioequivalent and therapeutically equivalent to AbbVie’s Reference Listed Drug (RLD), Carafate 1gm/10mL. This approval strengthens Strides’ position in the gastrointestinal treatment market and expands access to affordable peptic ulcer therapies in the U.S.
   

The peptic ulcers treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Proton pump inhibitors (PPIs)
• H2-receptor antagonists
• Antacids
• Antibiotics
• Cytoprotective agents
• Other drug types

Market, By Ulcer Type

• Gastric ulcers
• Duodenal ulcers
• Esophageal ulcers

Market, By Medication Type

• Branded
• Generics

Market, By Route of Administration

• Oral
• Parenteral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE